Capstone Therapeutics announced consolidated earnings results for the year ended December 31, 2013. For the year, the company reported net loss attributable to stock holders of $3,921,000 or $0.10 basic and diluted per share compared to net loss attributable to stock holders of $3,580,000 or $0.09 basic and diluted per share of prior year. Loss from continuing operations was $4,114,000 against $4,053,000 of prior year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.1 USD | -.--% |
|
-.--% | -21.15% |
Apr. 01 | Capstone Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Capstone Holding Corp. Announces Change in Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-21.15% | 646K | |
+22.15% | 46.56B | |
+44.76% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
+20.42% | 28.18B | |
-6.35% | 28.1B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- CAPS Stock
- News Capstone Holding Corp.
- Capstone Therapeutics Announces Consolidated Earnings Results for the Year Ended December 31, 2013